The FDA has approved Linzess (linaclotide) for treatment of irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and older.
The FDA approved perioperative durvalumab with FLOT chemotherapy for eligible patients with resectable Stage II-IVA gastric and GEJ cancers.
Tyruko (natalizumab-sztn), a biosimilar to Tysabri (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics.
Olezarsen receives FDA Breakthrough Therapy status for adults with severe hypertriglyceridemia following positive results from CORE and CORE2 trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback